Moleculin Biotech (MBRX) Set to Announce Earnings on Thursday

Moleculin Biotech (NASDAQ:MBRX) is expected to be announcing its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect Moleculin Biotech to announce earnings of ($8.87) per share for the quarter. Interested persons may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 19, 2026 at 4:00 PM ET.

Moleculin Biotech (NASDAQ:MBRX) last posted its quarterly earnings results on Thursday, August 13th. The company reported ($28.00) earnings per share for the quarter, beating the consensus estimate of ($31.00) by $3.00. On average, analysts expect Moleculin Biotech to post ($47.40) EPS for the current fiscal year and ($23.10) EPS for the next fiscal year.

Moleculin Biotech Stock Down 0.5%

Shares of Moleculin Biotech stock opened at $8.66 on Tuesday. The business’s fifty day simple moving average is $10.37 and its 200-day simple moving average is $38.40. Moleculin Biotech has a 52 week low of $3.23 and a 52 week high of $253.05.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on MBRX. Weiss Ratings restated a “sell (e+)” rating on shares of Moleculin Biotech in a research report on Thursday, October 15th. HC Wainwright cut their price target on Moleculin Biotech to $60.00 and set a “buy” rating for the company in a research note on Friday, August 28th. Finally, Wall Street Zen downgraded Moleculin Biotech from a “sell” rating to a “strong sell” rating in a research report on Saturday. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $60.00.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on developing treatments for cancers and other serious diseases. The company uses its proprietary technology platforms to design drug candidates intended to address treatment resistance, improve drug delivery, and target biological pathways involved in disease progression.

Moleculin’s lead program is Annamycin, a liposomal formulation of the anthracycline doxorubicin being investigated for acute myeloid leukemia and soft-tissue sarcoma.